About Floris Engelhardt
Form D filings for Kano Therapeutics in 2024 list Floris Engelhardt as chief executive officer and director.
Floris Engelhardt first appears on SEC filings in 2024.
Experience
This experience comes from SEC filings. The years are when the filings name Floris Engelhardt in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Floris Engelhardt works with at each company, as listed on that company's latest Form D.
Kano Therapeutics Inc. · Form D, May 20, 2024
AD
Ann DeWitt
Director
JV
John Vroom
Director